Infectious complications after autologous peripheral blood progenitor cell transplantation (PBPCT) have been reported in a few studies including small patient numbers. The present study was performed to assess the incidence, types, outcome and factors affecting early and late infections in 150 patients aged 18 to 68 years (median 46.5) who underwent high-dose therapy, with G-CSF. Patients were kept in reverse isolation rooms and received antimicrobial chemoprophylaxis with oral quinolone and fluconazole. One hundred and fifteen patients (76.7%) developed fever (median 3 days, range 1-29); 20 patients (55.5%) had Gram-positive and 13 (36.2%) Gram-negative bacterial infections. There were no fungal infections or infection-related deaths. Mucositis grade II-IV (P ‫؍‬ 0.0001; odds ratio 3.4) and Ͼ5 days on ANC Ͻ100/l (P ‫؍‬ 0.0001; odds ratio 2.3) correlated with development of infection. Only days with ANC Ͻ100/l affected infection outcome (P ‫؍‬ 0.0024) whereas the antibiotic regimen did not. After day ؉30 there were four cases of bacterial pneumonitis (2.7%), one case of fatal CMV pneumonia (0.8%) and 20 of localized VZV infection (13.3%). Reduction of neutropenia duration with PBPCT and G-CSF is not enough to prevent early infectious complications since only a few days of severe neutropenia and mucositis are related to development of early infections. However, no infection-related deaths were seen. Although Grampositive organisms were the major cause of bacteremia, a glycopeptide in the empirical antibiotic regimen did not affect infection outcome. In PBPCT recipients, early and late opportunistic infections were notably absent, which was at variance with what was seen with bone marrow recipients. Efforts should be made to prevent mucositis and neutropenia and identify new strategies of antibacterial prophylaxis.
High-dose therapy (HDT) followed by allogeneic bone marrow transplantation (BMT) is potentially curative for some hematological diseases. Infections are well described in this context and they are still a major cause of morbidity and mortality. 1 Indeed, during the period of neutropenia, bacterial infections such as bacteremia and pneumonitis occur in 15-50% and 4-20% of patients, respectively, 2 while fungal infections such as candidiasis and aspergillosis affect about 11% 3, 4 and result in substantial mortality. After the first and throughout the third and fourth months (ie in the immunosuppressed phase), cytomegalovirus (CMV) infects 30-70% of patients 5 and mortality is around 15-20%. 6 After the fourth month, during chronic immunosuppression due to graft-versus-host disease (GVHD) or its preventive therapy, opportunistic infections occur in about 15% of patients. 7 Autologous BMT is an alternative to allogeneic BMT for patients without a matched donor. Disease relapse is the main problem in these patients, although infections are the principal cause of early morbidity and mortality. Indeed, during the phase of prolonged marrow aplasia, the incidence of bacterial and fungal infections is similar to that found after allogeneic BMT, with a mortality of around 5-10%, 8 whereas CMV and other opportunistic infections are rare. 9 For some years, peripheral blood progenitor cells (PBPC) have been preferred for autologous transplantation because of ease of collection of high numbers of CD34 ϩ cells after chemotherapy followed by growth factor administration. 10, 11 When sufficient CD34 ϩ cells are infused, hemopoietic recovery after HDT is rapid compared to that seen with BMT. 12, 13 This has reduced mortality for autologous transplantation to below 5%. 14 While infectious complications in allogeneic and autologous BMT are well described, few studies have focused on infections after peripheral blood progenitor cell transplantation (PBPCT). 8, [14] [15] [16] Also, these studies include relatively few patients and whereas Kolbe et al 16 reviewed infections in only PBPCT recipients, others 8, 14, 15 have included patients treated with autologous BMT.
We report 150 consecutive patients who underwent HDT followed by autologous PBPCT at a single institution. The aim of the present study was to assess the incidence, types and outcome of early and late infections and the factors affecting their development and outcome.
Patients and methods

Patient characteristics and HDT
Patient characteristics are summarized in Table 1 : median age was 47 years (range 18-68) and performance status was very good (у1 WHO) in the majority of patients. More than 80% of patients had lymphoproliferative disorders, about 10% solid tumors and 8% acute leukemia. About half the patients had received at least three different chemotherapy regimens whereas only 12% had received radiotherapy. Thirty-seven patients (24.7%) had hypogammaglobulinemia. While 16% of patients were in first complete remission (I CR) and had received HDT as consolidation therapy, all the others (84%) received HDT as salvage therapy.
Conditioning regimens were chosen according to the underlying disease: lymphoproliferative disorders were treated with high-dose melphalan alone (12%) or with other regimens (BEAM, thiotepa, busulfan or mitoxantrone: 56%); TBI and chemotherapy were administered to only 9.3% of patients. Leukemias were treated with busulfancyclophosphamide (6.7%) and solid tumors ifosfamide, carboplatin and etoposide (ICE; 6.7%). Other conditioning regimens were also used occasionally.
Patient care
Central venous catheters (CVC) were placed in all patients prior to HDT and CVC care was performed according to During the aplastic phase all patients were kept in a positive-pressure HEPA-filtered room and received antimicrobial prophylaxis with oral chlorhexidine and amphotericin B four to five times daily, oral ciprofloxacin 2 ϫ 500 mg/day, oral fluconazole 100-400 mg/day (136 patients) or itraconazole 300 mg/day (14 patients), and starting on the day of transplant (day 0), intravenous acycloguanosine 15 mg/kg/day. Intravenous immunoglobulin (IVIG) prophylaxis was given weekly to 96 patients (64%).
Clinical examination was performed daily and body temperature was measured two to three times a day. Routine surveillance cultures from nose, rectum, urine and mouthwash were performed weekly.
If the body temperature was Ͼ38.3°C, blood cultures were taken from peripheral blood and CVC and repeated after 1 h and alternate days for as long as fever and/or bacteremia persisted. Empirical parenteral antibiotic therapy was started and continued for 5 days until resolution of clinical and microbiological findings. The empirical antibiotic regimen included a third-generation cephalosporin plus an aminoglycoside or carbapenemic; a glycopeptide was added at the discretion of the attending physician. Antibiotic regimens were modified according to microbiological results. If fever persisted empirical amphotericin B (AMF-B) was added 7 days after the beginning of antibiotic therapy.
On day 0 and ϩ1, patients received a median of 6 ϫ 10 6 /kg CD34 ϩ cells (range 0.5-61.3). All patients received G-CSF 5 g/kg/day until the WBC count reached 5000/l starting on the 5th day after PBPCT; irradiated blood products were infused to maintain hemoglobin and platelet levels above 8 g/dl and 10 000/l, respectively.
From day ϩ15 to day ϩ30 patients received trimethoprim-sulphamethoxazole 2 ϫ 1920 mg/day twice a week.
PBPC mobilization, collection, measurement and cryopreservation
Priming chemotherapy included high doses of drugs such as cyclophosphamide 7 g/m 2 in 73 patients (48.7%), etoposide 2 g/m 2 in 14 (9.3%) and DHAP regimen in 43 patients (28.7%). In the remaining 20 patients (13.3%) other primers were used. Starting 24 h after the discontinuation of chemotherapy, G-CSF (filgrastim) 5 g/kg/day was administered subcutaneously until leukapheresis.
Aphereses were carried out using a Fenwall CS 3000 Plus automatic blood cell separator (Baxter, Santa Ana, CA, USA).
Harvest size was calculated after each leukapheresis by total nucleated cell count, MNC count, cytofluorimetric count of CD34 ϩ cells and clonogenic assay of committed progenitors. The final product was cryopreserved in 10% DMSO with a Planer R201 controlled-rate freezing device and stored at 196°C in liquid nitrogen.
CD4
ϩ T cells counts CD4 ϩ T cell counts were performed on days ϩ30, ϩ60, ϩ90 and subsequently every 3 months until reconstitution; they were identified with 13B8-2 murine monoclonal antibody (Immunotech, Marseille, France) using a Becton Dickinson (Erembodegen-AACSI, Belgium) FacScan.
Definition criteria
Early infection was defined as an infection arising within 30 days after transplant and late infection as one that arose later.
A febrile episode was defined as fever Ͼ38.3°C or two episodes of fever Ͼ38°C (axillary temperature) in the absence of an obvious noninfectious cause of fever such as blood products transfusion, cytotoxic drugs administration or tumor fever.
Microbiologically documented infection was defined as signs or symptoms of infection with an organism isolated on blood culture, histological material or from a definite site of infection. Clinically documented infection was defined as signs or symptoms of infection with an identifiable site of infection (eg pulmonary infiltrate, cellulitis) without isolation of an organism. Fever was defined as of unknown origin (FUO) when no site was identified and microbiological evaluation failed to yield any pathogen.
Bacteremia was defined as a febrile episode with a positive blood culture with any organism except for coagulasenegative staphylococci or skin coryneforms, for which two consecutive positive cultures were required.
CVC-related infection was defined as clinical evidence of infection accompanied by a positive blood culture (two consecutive cultures for coagulase-negative staphylococci) with or without exit-site infection when a distant primary site of infection could not be identified; tunnel infection with or without positive blood culture was related to CVC infection.
Fungal infection was defined 'proven' when fungi were recovered from a normally sterile site or from biopsy or autopsy specimens and the clinical presentation was compatible. Fungal infection was defined 'probable' when compatible radiographic and clinical findings were present combined with identification of fungi from a contiguous non-sterile site.
CMV pneumonia was defined as the presence of signs or symptoms of pneumonitis and CMV recovered from bronchoalveolar lavage fluid or lung tissue in cell culture, or by detection of early antigenic fluorescence foci. 18 Varicella zoster virus (VZV) infection was defined as the appearance of typical vesicular skin lesions with a dermatomal distribution, and post-herpetic neuralgia as dermatomal pain persisting longer than 28 days after infection onset. 19 Response to antibiotics was classified as 'improvement' if temperature returned to normal and all signs and symptoms disappeared without changes or the addition of other antibiotics, and as 'failure' if temporary, minimal or no response occurred, or if antibiotics changes or additions were required. 20 Neutropenia was defined as an absolute neutrophil count (ANC) Ͻ500/l and severe neutropenia as ANC Ͻ100/l.
Mucositis was defined according to WHO criteria; the presence of ulcers (grade II-IV) was defined as severe mucositis.
Neutrophil engraftment was defined as the first day on which the ANC exceeded 500/l for 2 consecutive days. Platelet transfusion independence was defined as the first day on which the platelet count exceeded 20 000/l, unsupported.
Study design and statistical methods
From June 1991 to December 1997, 172 patients received autologous transplants at our institution, 22 with bone marrow and 150 with PBPC. This retrospective cohort included the 150 consecutive patients who underwent PBPCT. Charts were examined by the authors and reviewed by three physicians skilled in different specialities (hematology, microbiology and radiology). Definitions and end-points were constructed prior to chart examination. Data were analyzed by descriptive statistical methods and differences between groups were calculated using Chisquare or Fisher's exact test.
Factors affecting infection development were investigated using logistic stepwise analysis and those affecting fever duration by the Cox proportional hazards regression model; 21 the variables were selected using a stepwise backward method and were excluded from the model when the probability was Ͼ0.1. Results are presented as odds ratios and significance. The best cut-offs of continuous variables (age, CD34 ϩ cells, days on ANC Ͻ100/l, days on ANC Ͻ500/l) were ascertained empirically using correlation coefficients. A cut-off for CD4 ϩ T cells equal to 200/l was chosen, since a count below 200/l is associated with a higher risk of opportunistic infections in HIV-positive patients.
Probabilities of events were obtained using the KaplanMeier method 22 and the groups were compared by the logrank test. Probability of fever duration was calculated from day of fever onset to day of fever resolution and probability of hospital stay from day 0 to discharge.
Significance was established at P Ͻ 0.01 (two-sided) because of the high number of statistical comparisons made.
Data were analyzed using an SPSS statistical package (SPSS, Chicago, IL, USA).
Results
Transplantation, supportive care and hemopoietic reconstitution
PBPC were infused on day 0 and ϩ1; 61.3% of patients received у5 ϫ 10 6 /kg CD34 ϩ cells and only 10% received Ͻ2.5 ϫ 10 6 /kg CD34 ϩ cells. All patients became neutropenic; days with an ANC Ͼ100/l ranged from 1 to 39 (median 5; 90th 11) whereas days with an ANC Ͻ500/l ranged from 2 to 44 days (median 7 days; 90th 15 days). All patients recovered an ANC Ͼ500/l within 8-49 days (median 11; 90th 14); all but six patients (4.7%) became transfusion-independent (platelets Ͼ20 000/l) within a median of 13 days (range 8-329ϩ; 90th 39 days).
Severe mucositis (grade II-IV WHO) was observed in 66.7% of patients; nevertheless, only 26.7% of patients required total parenteral nutrition. 
Incidence and types of early infections
Of the 150 patients, 115 (76.7%) experienced a febrile episode within 30 days of transplant (Table 2) ; 102 (88.7%) developed fever during the period of severe neutropenia, four (3.5%) during neutropenia and nine patients (7.8%) became febrile when the ANC was above 500/l. Probability of fever onset during neutropenia is shown in Figure 1 . Fever of unknown origin (FUO) was observed in 68 patients (59.1%); in 40 patients (34.8%) infection was microbiologically documented (36 bacteremias, two pneumonias, one enterocolitis and one vaginitis) and in seven Days of neutropenia Figure 1 Probability of fever onset during neutropenia (day 0 represent the first day of neutropenia). Only 15% of patients developed fever within the 5th day whereas 50% of patients developed fever between 6th and 8th day and 30% between 9th and 11th day of neutropenia.
(6.1%) it was documented clinically ( Table 3) . Gram-positive bacteria were the most frequent cause of bacteremia (20 patients, 55.5%) whereas gram-negative bacteremia was observed in 13 patients (36.2%). Two cases of bacteremia were polymicrobic and one was due to an anerobic bacterium (Table 3) .
Seven patients (6.1%) had a CVC-related infection (Table 2 ) and nine (7.8%) had pneumonia (Table 3) .
Fungal colonization occurred in 40 (26.7%) of patients, Candida spp in 35 patients (87.5%) and Aspergillus spp in five (12.5%). No differences in colonization were found between patients given prophylactic fluconazole doses below or above 200 mg/day (P ϭ 0.3). Neither 'probable' nor 'proven' fungal infections were found even though 10 patients (8.7%) received empirical AMF-B for a median of 9 days (range 5-28 days). On day ϩ10 after transplant, one patient (0.9%) suffered from diffuse HZV infection which responded promptly to acyclovir; nevertheless, severe residual post-herpetic neuralgia in the right arm occurred and persists after 33 months. Two patients (1.7%) had chest X-ray evidence of interstitial pneumonitis not CMV-related.
Factors affecting early infection development
Univariate analysis showed that Ͼ5 days of an ANC Ͻ100/l, Ͼ7 days of an ANC Ͻ500/l, mucositis grade II-IV and underlying disease with marrow involvement were associated with a higher risk of early infection whereas age, sex, performance status, previous chemotherapy, disease status at transplant, preparative regimen, number of CD34 ϩ cells infused, hypogammaglobulinemia, IVIG prophylaxis and parenteral nutrition were not. Multivariate analysis showed that factors affecting early infection occurrence were severe mucositis and duration of severe neutropenia (Table 4) .
Response to therapy of early infections and stay in hospital
Of the 115 febrile patients, 76 (66.1%) were treated with three empirical antibiotics (third-generation cephalosporin, aminoglycoside and glycopeptide) and 39 (33.9%) with an antibiotic regimen not containing a glycopeptide (third-generation cephalosporin plus aminoglycoside, third-generation cephalosporin or uridopenicillin). With regard to median neutropenia duration (6 days vs 6 days; P ϭ 0.2), no difference was found between the group of patients treated or not treated with a glycopeptide as regards time of fever resolution (Figure 2 ), first-line treatment failure and median duration of antibiotic therapy. No difference was found between gram-positive and gram-negative infections as regards median fever duration (3 days vs 3 days; P ϭ 0.2) or median antibiotic duration (8 days vs 10 days, P ϭ 0.5). Univariate analysis showed that bad performance status, disease status at transplant other than CR, Ͼ7 days of an ANC Ͻ500/l, Ͼ5 days of an ANC Ͻ100/l and FUO were each associated with longer fever duration. Multivariate analysis showed that the only factor affecting fever duration was days of an ANC Ͻ100/l (odds ratio 1.4, 95% confidence interval 1.2-1.6, P ϭ 0.0024) (Table  5) ; the proportion of patients remaining febrile was significantly higher among those with severe neutropenia Ͼ5 days duration than in patients with neutropenia of shorter duration (Figure 3) .
The proportion of patients with a longer hospital stay was significantly higher in the febrile than in the non-febrile group (Figure 4) .
Incidence, type and outcome of late infections
Twenty-six patients (17.3%) experienced an infection after day ϩ30 from transplant. Of these, six (5.1%) became febrile between days ϩ35 and ϩ60; chest X-ray showed pulmonary infiltrates in five patients (3.4%), lobar infiltrates in three and interstitial lesions in two patients; the last two were admitted again because of severe respiratory syndrome; one patient quickly became afebrile on erythromycin whereas the other was CMV-positive on day ϩ35 and died on day ϩ60 from respiratory failure despite combination gancyclovir and immunoglobulin treatment. Autopsy confirmed CMV pneumonia. In this patient, the CD4 ϩ T cell count on day ϩ30 was 131/l. The three patients with lobar pneumonia were successfully treated with broadspectrum antibiotics on an outpatient basis. One patient had FUO and was successfully treated with broad-spectrum antibiotics. In these six patients, all with lymphoma, the median CD4 ϩ T cell count on day ϩ30 was 293/l (range 131-480).
Twenty patients (13.3%) developed VZV infection at a median of 7 months from transplant (range 1.6-35.6 months). All patients had localized infection, although postherpetic neuralgia was fairly generalized and protracted. All patients but one had lymphoproliferative disorders. The Kaplan-Meier estimate of hospital stay. The proportion of patients staying in hospital was significantly higher in febrile than in nonfebrile patients (log-rank test P ϭ 0.0003).
probability of VZV infection was 12% at 1 year and 20% at 2 years ( Figure 5 ). The median CD4 ϩ count before infection was 326/l (range 113-1073); however, the group of patients with CD4
ϩ T cell counts р200/l on day ϩ30 had an incidence of VZV infection of 29.4% whereas in the group of patients with CD4
ϩ T cell counts Ͼ200/l the incidence was 9.1% (P ϭ 0.0035). The probability of VZV reactivation at 1 year was 35% in the first group vs 3% in the second one (log rank test P ϭ 0.0020).
Discussion
HDT followed by stem cell transplantation is increasingly used for the treatment of malignant and non-malignant diseases. 23 However, this procedure results in prolonged neutropenia, profound immunosuppression and interruption of mucocutaneous barriers leading to various infectious complications. In BMT recipients, prolonged and profound neutropenia in the pre-engraftment period is accompanied by severe bacterial and fungal infections associated with a high mortality rate. 2 PBPCT and growth factors have drastically shortened the duration of neutropenia; 12, 14, 24 in our study the duration of severe neutropenia was р9 days in more than 90% of the patients. Despite this short duration of neutropenia, infectious complications occurred in more than 75% of our patients; likewise, the only study comparable with ours found a similarly high incidence. 16 The majority of our patients experienced only one febrile episode; duration of the febrile episode was short and 90% of patients defervesced within 8 days; indeed, as shown in Figure 1 , fever developed quite late after neutropenia onset, near the time of neutrophil recovery. The short period of neutropenia probably favors the rapid resolution of bacterial infections, since no early infection-related deaths occurred in our cohort of 150 patients, similar to the series of Kolbe et al 16 and Nosanchuk et al. 8 We demonstrated that the only factor affecting the outcome of early infection after PBPCT was duration of severe neutropenia. However, characteristics of the pathogen involved are also likely to play a substantial role even though this is difficult to assess, and in our patients no difference in outcome was found between grampositive and gram-negative infections. Presence of a glycopeptide in the antibiotic regimen containing a third generation cephalosporin and aminoglycoside did not affect the outcome of febrile episodes. A glycopeptide should therefore not be routinely added to the above regimen before randomized trials have demonstrated its usefulness in this group of patients, at variance with the suggestion of Kolbe et al. 16 In about 60% of patients the febrile episode was classified as FUO, a figure similar to that reported by Kolbe et al 16 (53%) and Mossad et al 14 (56%). As regards documented infections, Gram-positive organisms were the major cause of bacteremia as previously reported. 8, 14, 16 The increased frequency of Gram-positive infections over the last few years has been attributed to prophylaxis with fluoroquinolones, 25 severe mucositis and use of CVC. 26 However, we observed a low incidence (6%) of catheter-related infections. Despite prophylaxis with quinolones, incidence of Gram-negative bacteremia in our cohort (36%) was higher than that reported by Kolbe et al 16 (8%) and Mossad et al 14 (18%) both using the same antimicrobial prophylaxis. In our unit there is a long tradition of using quinolones for antibacterial prophylaxis and this can produce a selection of resistant gram-negative strains. Our unpublished data show that the incidence of quinolone-resistant gram-negative and gram-positive bacteria is higher than the 3 and 9% reported in a recent meta-analysis. 27 This could explain the high incidence of gram-negative bacteremia in our cohort, and highlights the benefit of continuing such prophylaxis in all patients undergoing PBPCT.
Many 2, 27, 28 have hypothesized that mucositis is responsible for the increase in bacteremias, particularly those due to gram-positive organisms; this has not been statistically demonstrated, however. Our multivariate analysis identified not only severe neutropenia but also severe mucositis as significant risk factors for developing infections. However, previous studies 8, 14 found that duration of neutropenia was the single factor most predictive for development of infections. Therefore, we were able to demonstrate what had previously been only hypothesized, ie that mucosal barrier disruption facilitates entry into the blood stream of grampositive and gram-negative bacteria (eg quinoloneresistant) in patients without neutrophils, resulting in a high incidence of bacteremia in patients who have undergone PBPCT, in spite of the short duration of severe neutropenia. However, molecular studies have demonstrated that most Staphylococcus epidermidis bacteremias are not catheterassociated but originate from the alimentary tract. 29 Although, it is difficult to reduce the intensity of conditioning therapy, administration of cytoprotectors is simpler and may reduce the severity of HDT-related mucositis. 30 There were no fungal infections in our series, in line with previous investigations which have included PBPCT recipients, 8, [14] [15] [16] because of the shorter duration of severe neutropenia in this patient population. In BMT recipients the prophylactic administration of 200 mg twice a day fluconazole has been shown to be useful in preventing fungal infections 31 which arise in 5-15% of these patients. 3, 4, 32 No randomized clinical trials have so far investigated the effect of fluconazole in PBPCT recipients; however, such a study is unlikely to be conducted owing to the very low incidence of fungal infections and the limited empirical use of AMF-B in these patients. The low incidence of fungal infections in PBPCT patients and the significant cost of fluconazole could make its cost-benefit ratio unfavorable. Our data, in accordance with previous findings, 8, 14, 16 suggest that in PBPCT recipients routine surveillance cultures and antifungal prophylaxis should be undertaken only in high-risk patients with prolonged severe neutropenia. 4, 32 For the same reasons, we believe that empirical AMF-B should be administered only to patients suffering from at least 'probable' fungal infection.
Late infections occurred in less than 20% of patients. Pneumonias typically developed in the second month after transplant. Lobar pneumonitis is easier to treat on an outpatient basis than is interstitial pneumonitis. In PBPCT patients, CMV pneumonia was unusual (less than 1%), as reported for autologous BMT by the EBMT Registry, 9 but it is associated with a substantial mortality. Pneumonitis is likely to be due to impairment of immune function during the second month after PBPCT since all patients had a CD4 ϩ count of Ͻ500/l. However, at variance with BMT recipients, late fungal infections, particularly Pneumocystis carinii, and encapsulated bacteria pneumonias were not observed in our cohort, possibly due to the reduced level and duration of the immune function impairment induced by PBPCT compared with the BMT procedure. 33 VZV infection was the most common infection after day ϩ30 (77%); its incidence in our sample was 13%, ie half that reported for autologous BMT 34 and one third of that reported for allogeneic BMT. 35 These findings, besides confounding factors such as different ages, follow-up or patient selection criteria among studies, could be associated with degree of immune suppression since the CD4 ϩ T cell population seems to correlate with VZV reactivation in immunocompromised patients. 36, 37 Indeed, we observed that in patients with CD4
ϩ counts Ͻ200/l, VZV infections were 29% and developed within 1 year, substantially in line with BMT data. Therefore, after PBPCT, patients appear to be less severely immunocompromised than after BMT which could also explain the lower frequency of diffuse and sev-ere VZV infections in PBPCT recipients. Even though the incidence of VZV infection is low in PBPCT recipients, a vaccination program could be useful to reduce its disabling sequelae.
In conclusion, the infectious complications arising after PBPCT followed by G-CSF can be distinguished from those occurring after autologous and allogeneic BMT because of reduced severity, lower incidence of pneumonia and virtual absence of early and late fungal and other opportunistic infections; consequently, mortality was extremely low. However, the reduced duration of neutropenia seen with PBPCT and G-CSF is not enough to prevent early infectious complications since very few days of severe neutropenia and mucositis are necessary to allow occurrence of early infections. Although Gram-positive bacteremias were the most common infection, a glycopeptide added to the standard empirical antimicrobial regimen did not improve outcome. In PBPCT recipients, epidemiological data suggest that IVIG prophylaxis, quinolone prophylaxis, antifungal prophylaxis and empiric AMF-B should be used with caution. Neutropenia remains a significant risk factor for early infections but mucositis emerged as a stronger risk factor for infection development in PBPCT recipients.
The most immediate challenges now are reduction of mucositis (eg with fractioned HDT, cytoprotectors), further reduction in duration of severe neutropenia or its prevention (eg with fractioned HDT or progenitor cell expansion) and identification of new, effective strategies of antibacterial prophylaxis.
